Aristolochic acid
This article was originally published in The Tan Sheet
Executive Summary
Thirteen Treasure of the East products containing herb linked to kidney failure and increased cancer risk recalled by Ithaca, N.Y.-based Blue Light, FDA announces June 20. Total of 1,213 bottles of powder or capsules distributed nationwide, mainly to specialty retailers and herbal practitioners; no illnesses have been reported, agency notes. FDA Acting Principle Deputy Director Bernard Schwetz, PhD, recently asked health professionals to assist in cataloging renal adverse events possibly related to ingestion of frequently recalled herb (1"The Tan Sheet" June 11, In Brief)
You may also be interested in...
FDA Notifies Import Agents To Watch For Contaminated Chinese Diet Pills
FDA has warned its import operations personnel to be on alert for the Chinese weight-loss products Chasu Gempi and Chasu (Jianfei) Diet Capsules due to their potential health risks, the agency said in an Aug. 13 public health alert
Aristolochic acid
FDA reiterates plea for health professionals to review cases of "unexplained" renal disease, urothelial tract tumors to determine if patients used supplements. In statement published in June 6 JAMA, Acting Principal Deputy Director Bernard Schwetz, PhD, says related cases should be reported "as soon as possible" to agency's MedWatch program. FDA outlined concerns regarding aristolochic acid-containing supplements in three separate letters to health professionals, consumers and industry in early April (1"The Tan Sheet" April 16, p. 9)
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC